Groupama Asset Managment Buys 19,994 Shares of BioNTech SE (NASDAQ:BNTX)

Groupama Asset Managment increased its stake in BioNTech SE (NASDAQ:BNTX) by 30.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,725 shares of the company’s stock after buying an additional 19,994 shares during the quarter. Groupama Asset Managment’s holdings in BioNTech were worth $9,764,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of BNTX. Jones Financial Companies Lllp raised its position in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares during the period. Quintet Private Bank Europe S.A. lifted its stake in shares of BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after acquiring an additional 700 shares during the last quarter. Allianz SE purchased a new position in BioNTech during the 4th quarter valued at $90,000. GAMMA Investing LLC boosted its holdings in BioNTech by 48.2% during the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after acquiring an additional 300 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new position in BioNTech in the 4th quarter valued at $137,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BNTX. Truist Financial initiated coverage on shares of BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 target price for the company. Morgan Stanley decreased their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. BMO Capital Markets lifted their target price on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Finally, Wells Fargo & Company initiated coverage on BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $143.73.

BioNTech Price Performance

NASDAQ BNTX opened at $91.06 on Tuesday. The firm’s fifty day simple moving average is $110.99 and its two-hundred day simple moving average is $113.65. The firm has a market capitalization of $21.85 billion, a P/E ratio of -43.36 and a beta of 0.30. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 EPS. Analysts forecast that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.